Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Slow Off-Rate Modified Aptamer Arrays For Biomarker Discovery And Diagnostic Applications
J. Walker, E. Brody, L. Gold
Published 2012 · Chemistry
Save to my Library
Download PDFAnalyze on Scholarcy
DNA microarrays are currently playing a central role in biomarker discovery and in the development of diagnostics for personalized medicine. Our vision is a technology that enables proteomics in the same revolutionary way that DNA microarrays enabled nucleic acid-based omics, allowing simple, reliable, sensitive, accurate, quantitative, and highly multiplexed measurements for the discovery of protein biomarkers and the development of new diagnostics to transform personalized medicine. We recently reached an important milestone, making unbiased protein biomarker discovery routine and fast. Microarrays played a prominent role in our experiments and will be central to the ongoing evolution of our platform. Our technology is powered by a new class of single-stranded DNA-based protein affinity binding reagents we call SOMAmers—slow off-rate modified aptamers. SOMAmers have a dual nature that is essential in our work: under normal conditions (e.g., physiologic in serum), SOMAmers fold into specific shapes that bind target proteins with high affinity (sub-nM K d), but when SOMAmers are denatured, they can be detected and quantified by hybridizing to a standard DNA microarray.
This paper references
The Coordinates of Truth
G. Nabel (2009)
Crystal structure of NF-κB (p50)2 complexed to a high-affinity RNA aptamer
D. B. Huang (2003)
Magnitude of Underascertainment of Impaired Kidney Function in Older Adults with Normal Serum Creatinine
S. Giannelli (2007)
The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array.
R. Ostroff (2010)
From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay
S. Krämer (2011)
Rules of evidence for cancer molecular-marker discovery and validation
D. Ransohoff (2004)
T7 RNA polymerase transcription with 5-position modified UTP derivatives.
Jonathan D. Vaught (2004)
Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers.
M. C. Golden (2000)
In vitro selection of RNA molecules that bind specific ligands
A. Ellington (1990)
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Lance A. Liotta (2010)
Mass spectrometry based targeted protein quantification: methods and applications.
Sheng Pan (2009)
A HUPO test sample study reveals common problems in mass spectrometry-based proteomics
A. Bell (2009)
Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design
M. Pepe (2008)
The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease
Kunal Chaudhary (2010)
Biomarkers in acute and chronic kidney disease
T. Nickolas (2008)
The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum.
N. L. Anderson (2010)
Sources of bias in specimens for research about molecular markers for cancer.
D. Ransohoff (2010)
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.
C. Tuerk (1990)
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability.
D. Venturoli (2005)
High-content affinity-based proteomics: unlocking protein biomarker discovery
E. Brody (2010)
The Human Plasma Proteome
N. L. Anderson (2002)
Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection.
M. Okada (2005)
World Cancer Report
B. Stewart (2003)
Proteomics and diagnostics: Let's Get Specific, again.
D. Zichi (2008)
High resolution two-dimensional electrophoresis of proteins.
P. O'Farrell (1975)
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
N. Rifai (2006)
Aptamer-based multiplexed proteomic technology for biomarker discovery
L. Gold (2010)
Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity.
J. Hopfield (1974)
Crystal structure of an RNA aptamer bound to thrombin.
S. B. Long (2008)
Phases of biomarker development for early detection of cancer.
M. Pepe (2001)
Improving biomarker identification with better designs and reporting.
M. Pepe (2011)
Cancer Statistics, 2008
A. Jemal (2008)
Direct experimental evidence for kinetic proofreading in amino acylation of tRNAIle.
J. Hopfield (1976)
Let's get specific: the relationship between specificity and affinity.
B. Eaton (1995)
Photoaptamer arrays applied to multiplexed proteomic analysis
C. Bock (2004)
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma
Terri A. Addona (2009)
Expanding the chemistry of DNA for in vitro selection.
Jonathan D. Vaught (2010)
Photoaptamer Technology: Development of Multiplexed Microarray Protein Assays
D. Zichi (2002)
Biomarker discovery and clinical proteomics.
J. Silberring (2010)
Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery
Tracy R. Keeney (2009)
A stress test for mass spectrometry–based proteomics
R. Aebersold (2009)
A critique of the hypothesis, and a defense of the question, as a framework for experimentation.
D. Glass (2010)
The edges of understanding
A. D. Lander (2010)
Dimensionality is the issue: use of photoaptamers in protein microarrays.
Helen Petach (2002)
Metabolism of complement factor D in renal failure.
M. Pascual (1988)
Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era.
D. Kell (2004)
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.
E. Kassis (2009)
Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome
Haishan Lin (2008)
Sensitivity and Specificity of Photoaptamer Probes*
D. Smith (2003)
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
A. Levey (2007)
TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure.
I. C. van Riemsdijk-van Overbeeke (2000)
Atomic level architecture of group I introns revealed.
Q. Vicens (2006)
Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer
R. Ostroff (2010)
This paper is referenced by
Current Challenges in Nucleic Acid Synthesis
R. Hogrefe (2013)
Aptahistochemistry in diagnostic pathology: technical scrutiny and feasibility
Bakhtiar A. Bukari (2017)